Lupkynis Approved for Active Lupus Nephritis
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
Based on new findings from a study of patients with systemic lupus erythematosus, investigators suggest revising current guidelines to expand kidney biopsy indications to include isolated proteinuria of any grade.
Researchers evaluated the safety, mechanism of action, and preliminary efficacy of rituximab and cyclophosphamide followed by belimumab in the treatment of refractory lupus nephritis.
Severe renal arteriosclerosis in diagnostic lupus nephritis biopsies is associated with 9-fold higher odds of atherosclerotic cardiovascular disease.
A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.
Rate of thrombotic events lower for patients with mean HCQ blood levels >1,068 versus <648 ng/mL
In a randomized trial, belimumab (Benlysta) vs placebo added to standard therapy demonstrated superiority in achieving the primary efficacy renal response at 104 weeks.
Researchers evaluated the efficacy and safety of the induction treatment with mycophenolate mofetil and cyclophosphamide for lupus nephritis.
Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.
The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.